Diamino-pyrimidines and their use as angiogenesis inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C544S323000, C544S324000

Reexamination Certificate

active

10506447

ABSTRACT:
Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

REFERENCES:
patent: 97/19065 (1997-05-01), None
patent: 00/12089 (2000-03-01), None
patent: 02/59110 (2002-08-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reveiws 48: 3-26, 2001.
Sennlaub et al., The Journal of Clinical Investigation 107(6): 717-725, 2001.
Connell et al. Exp. Opin. Ther. Patents (2001) 11(1):77-144, especially p. 109 closing paragraph.
Klement et al., The Journal of Clinical Investigation 105(8): R15-R24, 2000.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Diamino-pyrimidines and their use as angiogenesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diamino-pyrimidines and their use as angiogenesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamino-pyrimidines and their use as angiogenesis inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3945881

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.